Publications by authors named "Michael Teufel"

Claim this Profile
B
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors.
Changhoon Yoo, Angela Lamarca, Hye Jin Choi, Arndt Vogel, Michael J Pishvaian, Michael Teufel

Future Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.
Noboru Yamamoto, Anthony Tolcher, Navid Hafez, Iwona Lugowska, Rodryg Ramlau, Michael Teufel

Onco Targets Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study.
Patricia LoRusso, Noboru Yamamoto, Manish R Patel, Scott A Laurie, Todd M Bauer, Michael Teufel

Cancer Discov· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial.
Michael Jeffers, Christian Kappeler, Iris Kuss, Georg Beckmann, Daniel H Mehnert, Michael Teufel

Gastric Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.
Birgit Geoerger, Bruce Morland, Irene Jiménez, Didier Frappaz, Andrew D J Pearson, Michael Teufel

Eur J Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.
Michael Teufel, Henrik Seidel, Karl Köchert, Gerold Meinhardt, Richard S Finn

Gastroenterology· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Matthew Smith, Chris Parker, Fred Saad, Kurt Miller, Bertrand Tombal, Michael Teufel

Lancet Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and characterisation of carnostatine (SAN9812), a potent and selective carnosinase (CN1) inhibitor with in vivo activity.
Jiedong Qiu, Sibylle J Hauske, Shiqi Zhang, Angelica Rodriguez-Niño, Thomas Albrecht, Michael Teufel

Amino Acids· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with -Mutated Hepatocellular Carcinoma.
Ho Yeong Lim, Philippe Merle, Karl Heinz Weiss, Thomas Yau, Paul Ross, Michael Teufel

Clin Cancer Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma.
Maria Kissel, Sandra Berndt, Lukas Fiebig, Simon Kling, Qunsheng Ji, Michael Teufel

Oncotarget· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
Jean-Luc Van Laethem, Hanno Riess, Jacek Jassem, Michael Haas, Uwe M Martens, Michael Teufel

Target Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Josep Tabernero, Heinz-Josef Lenz, Salvatore Siena, Alberto Sobrero, Alfredo Falcone, Michael Teufel

Lancet Oncol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase.
Michael Teufel, Vladimir Saudek, Jean-Pierre Ledig, Annie Bernhardt, Sylviane Boularand

J Biol Chem· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis